Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Overview of attention for article published in Journal of Thoracic Oncology, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

policy: 2 policy sources
twitter: 17 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 85 Dimensions

Readers on

mendeley: 101 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Entrectinib (Rozlytrek) for ROS1-positive Non-Small Cell Lung Cancer

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Konsultationfassung: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms: Langfassung der Leitlinie "Konsultationfassung: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms"

Cited by The Association of the Scientific Medical Societies in Germany on 27 May 2022

The Association of the Scientific Medical Societies in Germany (AWMF) is an umbrella organization of over 150 societies, and advises the government of the Federal Republic of Germany as well as the governments of the German federal countries in all topics of scientific medicine and medical research and classification.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.